Which group of hotly anticipated, next-generation therapies for a widespread health problem is expected to cost payers beaucoup bucks when they hit the market? If you said the new crop of hepatitis C treatments, you'd be half right. Pharmacy benefits managers say they're just as worried--perhaps even more so--by a coming class of pricey cholesterol fighters known as PCSK9 inhibitors. Report